Understand the source comparison
Peptides and Hyperbaric Oxygen HBOT Synergy: Protocol Comparison
Short-acting (BPC-157, TB-500, Selank) 30–60 min pre-HBOT 2.0–2.4 ATA 60–75 min 40–58% vs peptide alone Optimal for acute injury protocols; synchronise Cmax with hyperoxic peak Long-acting (Thymalin, CJC-1295, Ipamorelin) Immediately post-HBOT 2.0–2.5 ATA 60–9
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Short-acting (BPC-157, TB-500, Selank)
- 30–60 min pre-HBOT
- 2.0–2.4 ATA
- 60–75 min
- 40–58% vs peptide alone
- Optimal for acute injury protocols; synchronise Cmax with hyperoxic peak
- Long-acting (Thymalin, CJC-1295, Ipamorelin)
- Immediately post-HBOT
- 2.0–2.5 ATA
- 60–90 min
- 35–50% vs peptide alone
- Leverage post-session hyperoxic tail; allows slower tissue distribution
- GLP-1 agonists (semaglutide, tirzepatide)
- 90–120 min pre-HBOT
- 2.0 ATA
- 60 min
- 25–35% (limited data)
- Investigational; half-life too long for single-session optimisation
- Cognitive peptides (Cerebrolysin, Dihexa, P21)
- 45–60 min pre-HBOT
- 2.4 ATA
- 75–90 min
- 50–65% vs peptide alone
- Blood-brain barrier penetration enhanced by hyperoxia; combine with fasted state
- Growth hormone secretagogues (MK 677, Hexarelin, GHRP-2)
- 60 min pre-HBOT or immediately post
- 30–45% vs peptide alone
- Timing less critical due to pulsatile GH release; either protocol viable